Glaucoma therapy spinout Quethera will become a unit of drug manufacturer Astellas Pharma, providing exits to investors Cambridge Enterprise, UCEF III and UK2IS.
Quethera, a UK-based glaucoma therapy developer spun out from University of Cambridge, has been acquired by pharmaceutical firm Astellas Pharma for up to £85m ($108m) in cash and contingent commitments.
Founded in 2013, Quethera is creating drugs for treating glaucoma which use recombinant adeno-associated viral vectors (rAAV) to implant therapeutic genes in retinal cells.
Glaucoma is an ocular disease leading to blindness over the long-term, caused when the optic nerve has been damaged by pressure from built-up fluids.
Quethera believes…
